Health Bulletin 25/October/2021 Roshni Dhar25 Oct 2021 4:23 PM ISTHere are Top Health Stories of the dayDoctors cannot function under threat of being harassed, beaten up: High CourtThe Punjab and Haryana High Court...
Empagliflozin reduces insulin initiation in patients with diabetes and CVD: EMPA-REG OUTCOME trial Medha Baranwal25 Oct 2021 9:30 AM ISTUSA: Empagliflozin markedly and durably delays insulin initiation and substantial increases in insulin dose in patients with type 2 diabetes and...
Dr Reddys, MSN Labs launch of generic Empagliflozin may lead to court battle Farhat Nasim20 Oct 2021 2:01 PM ISTHyderabad: Taking head-on collision with Boehringer Ingelheim over blockbuster diabetes drug, two Indian pharma giants have recently launched their...
Empagliflozin reduces cardiac and renal risk in HFrEF patients, regardless of baseline NT-proBNP: Study Medha Baranwal9 Oct 2021 10:08 AM ISTUSA: Findings from the EMPEROR-Reduced trial showed higher baseline NT-proBNP concentrations to be associated with poor cardiorenal outcomes. However,...
Empagliflozin markedly improves BMI, blood sugar, BP in diabetics: SUPER GATE study Medha Baranwal18 Sept 2021 9:00 AM ISTBolu, Turkey: Empagliflozin add-on treatment improved metabolic parameters, blood pressure, and anthropometric measures and did not deteriorate kidney...
Empagliflozin significantly reduces hospitalization risk in patients of HFpEF, shows trial Dr. Kamal Kant Kohli30 Aug 2021 6:00 AM ISTFrance: SGLT-2 inhibitor, Empagliflozin significantly reduced heart failure-related hospitalizations, regardless of patient diabetes status, reveal...
FDA approves empagliflozin for heart failure with reduced ejection fraction in adults Dr. Kamal Kant Kohli21 Aug 2021 7:15 AM ISTThe U.S. Food and Drug Administration has approved Jardiance (empagliflozin) to reduce the risk of cardiovascular mortality plus hospitalization for...
EMPEROR-Preserved confirms success of Empagliflozin in HFpEF Hina Zahid8 July 2021 9:45 AM ISTEmpagliflozin therapy with specific benefits in patients with heart failure and preserved ejection fraction (HFpEF) may finally be on its way as the...
SGLT-2 Inhibitors may Improve Endothelial Function in T2D with CVD: Study Dr Kartikeya Kohli2 July 2021 9:00 AM ISTEmpagliflozin treatment has potential to improve endothelial function and has cardiovascular benefits, finds new study.
SGLT2 inhibitors improve biomarkers indicative of CVD risk in diabetes patients: Study Medha Baranwal2 Jun 2021 9:30 AM ISTTurkey: Both dapagliflozin and empagliflozin significantly improve plasma atherogenic biomarkers (AIP and TyG indexes), an indicator of cardiovascular...
Health Minister discusses side-effects of SGLT-2 inhibitors in the parliament Meghna A Singhania8 Feb 2021 4:10 PM ISTNew Delhi: With the rising incidence of diabetes in the country, SGLT-2 inhibitors have emerged as one of the preferred modality of treatment....
Empagliflozin Improves Heart Failure with rEF in Nondiabetic patients: Study MD Bureau31 Jan 2021 3:18 PM ISTIn patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk of hospitalization for heart failure by 30% to...
